A review of human biomonitoring data used in regulatory risk assessment under Canada's Chemicals Management Program

Abstract

As a part of the Chemicals Management Plan launched in 2006, the Government of Canada is assessing and managing, where appropriate, the potential health and ecological risks associated with approximately 4300 substances under the Canadian Environmental Protection Act (1999). Since that time, nearly 3000 substances have been assessed, with human biomonitoring (HBM) data playing an increasingly important role for some substances. Case studies are presented, including both inorganic and organic substances (i.e., selenium, triclosan, phthalates), which highlight the impact and overall role HBM has had in regulatory decision making in Canada for these three substances as well as criteria used in the application of HBM data in human health risk assessment. An overview of its limitations in terms of how and when HBM data can be applied, when assessing human health in a regulatory setting, is discussed as well as the role HBM data can play in priority setting.

Keywords: Biomarkers; Blood; Butylbenzyl Phthalate (PubChem CID: 2347); Chemicals management plan; Dibutyl Phthalate (PubChem CID: 3026); Diisobutyl Phthalate (PubChem CID: 6782); Dimethyl Phthalate (PubChem CID: 8554); Disodecyl Phthalate (PubChem CID: 439488); Disononyl Phthalate (PubChem CID: 590836); Environmental chemicals; Exposure; Forward dosimetry; Human biomonitoring data; Reverse dosimetry; Risk assessment; Selenium (PubChem CID: 6326970); Triclosan (PubChem CID: 5564); Urine.